Enliven Therapeutics, Inc. (ELVN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, specifically the Company's Annual Meeting of Stockholders. Enliven Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Burlingame, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation, increasing authorized common stock from 100,000,000 to 200,000,000 shares. The total authorized capital is now 210,000,000 shares (200M Common, 10M Preferred).
- Board Elections: Two Class III directors were elected: Richard Fair, M.B.A., and Lori Kunkel, M.D.
- Accounting Firm Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Voting Results
The filing details the results of five proposals voted upon at the Annual Meeting:
- Proposal 1 (Directors): Richard Fair received 50,534,439 votes "For" (152,188 "Withheld"). Lori Kunkel received 32,788,330 votes "For" (17,898,297 "Withheld").
- Proposal 2 (Auditor): Ratification passed with 56,119,493 votes "For" and 795 "Against".
- Proposal 3 (Share Increase): Approved with 54,711,846 votes "For" and 373,215 "Against".
- Proposal 4 (Say-on-Pay): Executive compensation approved with 47,572,153 votes "For" and 3,093,447 "Against".
- Proposal 5 (Say-on-Pay Frequency): Stockholders voted for annual advisory votes (49,028,648 votes for "One Year"). The next frequency vote is required no later than the 2032 annual meeting.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment (Exhibit 3.1) to confirm the exact timing of the share authorization increase.
- Review the Company's proxy statement for details on the executive compensation approved in Proposal 4.
- Monitor future filings for any immediate issuance of shares from the newly authorized pool of 100,000,000 additional common shares.
- Confirm the tenure of the newly elected directors (Richard Fair and Lori Kunkel) serving until the 2029 annual meeting.